about
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisNuclear receptors in bone physiology and diseasesManagement of endocrine disease: Secondary osteoporosis: pathophysiology and managementPartial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone massOsteopetrosis and its relevance for the discovery of new functions associated with the skeletonVascular calcifying progenitor cells possess bidirectional differentiation potentialsVascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1Id4, a new candidate gene for senile osteoporosis, acts as a molecular switch promoting osteoblast differentiationInvolvement of Prolyl Hydroxylase Domain Protein in the Rosiglitazone-Induced Suppression of Osteoblast DifferentiationTie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defectsPPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.Rescue of a primary myelofibrosis model by retinoid-antagonist therapyRetinoid X receptors orchestrate osteoclast differentiation and postnatal bone remodeling.Association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma gene and strength athlete status.Effects of exercise prior or during pregnancy in high fat diet fed mice alter bone gene expression of female offspring: An experimental study.Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers.Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency.MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action.Screening of protein kinase inhibitors identifies PKC inhibitors as inhibitors of osteoclastic acid secretion and bone resorption.Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitusInteractomics profiling of the negative regulatory function of carbon monoxide on RANKL-treated RAW 264.7 cells during osteoclastogenesisPeroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study.The role of mitochondria in the pathophysiology of skeletal muscle insulin resistance.Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetesPathobiology of Modic changes.Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1MED14 tethers mediator to the N-terminal domain of peroxisome proliferator-activated receptor gamma and is required for full transcriptional activity and adipogenesis.Quantification of Bone Fatty Acid Metabolism and Its Regulation by Adipocyte Lipoprotein LipaseInflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophagesThe Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus.Increased fat mass is associated with increased bone size but reduced volumetric density in pre pubertal childrenThe peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized ratsMolecular mechanism of thiazolidinedione-mediated inhibitory effects on osteoclastogenesis.PPARγ and the global map of adipogenesis and beyond.mTOR Inhibition Subdues Milk Disorder Caused by Maternal VLDLR LossIs there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects.Control of macrophage activation and function by PPARs.Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice.
P2860
Q24655666-A385B6A6-30CF-48D2-8905-277D633B768BQ26853017-C99EDA2A-64E9-41B3-A70E-58060E7BC4BCQ26998249-39F86EB9-63E1-4E42-B899-544089AC1862Q27334866-408A12F3-9054-4F01-A5BF-F8B2148F1588Q28085259-1588EE58-1455-4D98-9723-2B570286CC7BQ28486087-1F11EA36-37DE-4647-9B6C-8429DF96284FQ28508879-CBFA6F71-3D54-4EA2-A785-0074B6CEF76EQ28513923-AC698E22-5970-439D-8FEF-D48E2E92ED6DQ28548626-A302F736-1C98-4B80-8259-DBFC9DD56B54Q28593934-5101156A-F8C3-44CB-9B0F-A999F923E27FQ30241952-27B3EFD4-E2E5-41A6-A862-ED5BDCE07023Q30407836-4A19DF5D-25DB-4E20-8503-C729CE889CA3Q30557756-0B735BD4-8E52-4E9B-A17A-695F418B5092Q30619787-371F328E-4004-4D0F-B14C-79E30B9B057FQ31121358-083948DF-D855-4160-91C5-4FD58031BA8BQ33603794-55162041-2E72-403C-BF33-FE4F99518E4CQ33621757-437F5A66-07DB-4AF0-8540-7452BB12C03EQ33642053-0FD10841-A51A-44FB-BE0A-46415D8ADBA9Q33642155-6477B213-0AE6-4291-A61A-491DF8EDC0A5Q33717450-6E05F70F-BB30-4836-95D2-944C5C8602CEQ33729192-90D93F65-C446-45F6-9934-FCDFF0F93BF1Q33736122-55C1FA52-2853-4136-BDD2-9FBAA48F684CQ33736852-9947FF9D-968C-4FD9-90FB-671A29089A05Q33772312-6D79EFDA-BC0F-4C75-9B29-98E7916B8625Q33779662-3461512B-1898-42C0-864A-4030B72DC6CEQ33797616-0C0111B1-881E-44D8-A339-69D016DA8B21Q33816646-886EBB3A-0057-49A1-A01C-54A66937563FQ33821740-42C41579-09E9-49CB-8613-5948BF916F7EQ33826208-5490F489-0016-4C44-88ED-E256D6AF3627Q33838946-BAE56689-4EFE-422A-B034-2D1930D1F275Q33870766-D767635B-BE82-493D-BC0E-EC4226A67E00Q33874663-6C649C6A-3FD9-411E-BE1D-4D25D63C4991Q33907379-53675A80-4DF3-405D-BEFC-BEB9FB03446EQ33912894-CBD4F2A2-C55B-4420-8C7A-FD6DB9369035Q33916514-2725E257-919C-4F55-8A9F-10A66F26D344Q33924305-89C85F8E-2B13-4C20-928B-DFA16AD5F52BQ33926184-46ACD009-505C-4091-97CB-7ED7182666BBQ33960879-8074E080-F1B2-44FF-B490-503332FD0B62Q33962601-EC603F48-04D0-4C78-9BC7-377A78D37715Q33976093-A9E91C3A-963F-48BA-87A3-6E33DA5447AD
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
PPAR-gamma regulates osteoclastogenesis in mice.
@ast
PPAR-gamma regulates osteoclastogenesis in mice.
@en
PPAR-gamma regulates osteoclastogenesis in mice.
@nl
type
label
PPAR-gamma regulates osteoclastogenesis in mice.
@ast
PPAR-gamma regulates osteoclastogenesis in mice.
@en
PPAR-gamma regulates osteoclastogenesis in mice.
@nl
prefLabel
PPAR-gamma regulates osteoclastogenesis in mice.
@ast
PPAR-gamma regulates osteoclastogenesis in mice.
@en
PPAR-gamma regulates osteoclastogenesis in mice.
@nl
P356
P1433
P1476
PPAR-gamma regulates osteoclastogenesis in mice.
@en
P2093
Ling-Wa Chong
Yihong Wan
P2888
P304
P356
10.1038/NM1672
P407
P577
2007-12-02T00:00:00Z